Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Caris, Ontada form collaboration to advance molecular research, cancer care

Caris Life Sciences and Ontada announced a strategic and multi-faceted collaboration to advance molecular research and cancer care, enhance the healthcare delivery system and ultimately drive precision medicine by supporting life sciences companies in the development of next-gen oncology therapies.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Rybrevant + Lazcluze show improvement in OS versus osimertinib

Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA approves Ensacove for ALK-positive locally advanced or metastatic NSCLC

FDA approved Ensacove (ensartinib) for adult patients with anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.

December 06, 2024

Vol.50 No.45

Clinical Roundup

More cancers being treated with personalized therapies before surgery, National Cancer Database report shows

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.

December 06, 2024

Vol.50 No.45